Stories

Topic's Include: COVID-19 Resource Center addresses surge in delta variant infections, vaccination rates and hot spots, why masking recommendations change, and Mayo Clinic Q&A podcast: The COVID-19 delta variant has changed everything.

In her role as an education program manager, Heidi Zunker works to bring world-class digital education that’s rooted in Mayo Clinic expertise to thousands of people each year.

This week's research roundup features a risk of late-onset breast cancer in genetically predisposed women.

In late 2019, after months of looking for a reason for his rapid loss of muscular function, David Voeltz got an answer: he had necrotizing autoimmune myopathy. Today, after nearly two years of treatment, David has a renewed lease on life and keen appreciation for the Mayo Clinic team that confirmed his diagnosis.

Topics include: COVID vaccine urgency due to delta variant, Mayo Clinic announces new phase of vaccination requirement, Mayo Clinic Q&A podcast covers the delta variant and how to stop it, and a study shows masks offer protection as COVID infections increase.

This week's research roundup features a study on bipolar disorder cases that provide a new insight into underlying biology.

Top highlights include: Unvaccinated people at highest risk being infected by delta variant, strong immune response underlying kidney injury related to Covid, having certain type of antibodies help Covid patients avoid hospitalization, and you are you hesitant about Covid vaccine development?

For the last year, Emily Fernholz’s time has been consumed by COVID-19. But as the pandemic has eased, she’s turned her attention back to the usual business of Mayo’s Clinical Virology/Parasitology Laboratory: testing for virus-, parasite-, and vector-borne diseases.

This week's research roundup features a study on the prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma.

Top highlights include: Changes to outpatient visitor restrictions in Rochester, MN, Mayo Clinic Q&A podcast on the COVID-19 delta variant, and respiratory illnesses on the rise with symptoms similar to COVID-19.

Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.

This week’s research roundup features a study on acute treatments for episodic migraine in adults: A systematic review and meta-analysis.

Topic includes: new vaccine platform invented by Mayo enters COVID-19 clinical trial, Q&A on vaccination and precautions and the new work-life balancing act.